Your browser doesn't support javascript.
loading
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL.
Hengeveld, Paul J; Kolijn, P Martijn; Demmers, Jeroen A A; Doff, Wouter; Dubois, Julie M N; Rijken, Melissa; Assmann, Jorn L J C; van der Straten, Lina; Boiten, Henk Jan; Gussinklo, Kirsten J; Valk, Peter J M; Faber, Laura M; Westerweel, Peter E; Kater, Arnon P; Levin, Mark-David; Langerak, Anton W.
Afiliación
  • Hengeveld PJ; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
  • Kolijn PM; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Demmers JAA; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
  • Doff W; Proteomics Center, Erasmus MC, Rotterdam, the Netherlands.
  • Dubois JMN; Proteomics Center, Erasmus MC, Rotterdam, the Netherlands.
  • Rijken M; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
  • Assmann JLJC; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
  • van der Straten L; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
  • Boiten HJ; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
  • Gussinklo KJ; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Valk PJM; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
  • Faber LM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
  • Westerweel PE; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
  • Kater AP; Department of Hematology, Red Cross Hospital, Beverwijk, the Netherlands.
  • Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Langerak AW; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
Hemasphere ; 7(10): e951, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37731707

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Hemasphere Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Hemasphere Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos